In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate-or poor-risk AML. Relapse incidence was lower with MAC in poor-and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate-and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with AML in first CR1 if the leukemia is considered to be of intermediate or high risk, based on cytogenetic and molecular data. [1] [2] [3] [4] [5] [6] [7] The conditioning intensity is varied, with reduced intensity (RIC) conditioning regimens usually being given to older patients, whereas young patients traditionally receive myeloablative regimens (MAC). 8, 9 In patients aged 40-60 years, both types of regimens are used, with little knowledge about factors that would lead physicians to prefer one over the other. The presence of comorbidities may obviously favor the use of RIC regimens. Previous studies have shown that RIC regimens were associated with somewhat higher relapse risks but lower risks of nonrelapse mortality (NRM). Conversely, MAC regimens were associated with lower relapse risks, but higher NRM in diseases where this could be studied. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We therefore hypothesized that in low intermediate-risk disease based on cytogenetic classification, RIC is superior to MAC, whereas in high-risk leukemia, MAC is superior to RIC given higher anti leukemic activity.
PATIENTS AND METHODS
This study included 2974 eligible patients out of 5388 with AML transplanted in CR1 in 2000-2011, aged 40-60 years. Only patients with available cytogenetics to classify the risk status at diagnosis 21 were included. All patients were reported to the European Group for Blood and Marrow Transplantation (EBMT) by 214 centers. Only sibling or unrelated donors and marrow or peripheral blood stem cell transplants were considered. Regimens were classified as MAC (n = 1638) or RIC (n = 1336) based on published criteria. 8, 9 MAC regimens were cyclophosphamide+TBI (48 Gy) ± other drugs (n = 740), or cyclophosphamide+busulphan (48 mg/kg) ± other drugs (n = 652) or other regimens (n = 246); RIC regimens were fludarabine+low-dose TBI o6 Gy (n = 303), fludarabine+busulphan (⩽8 mg/kg; n = 578), or fludarabine+melphalan (n = 305) or other regimens (n = 150). Excluded were patients receiving cord blood transplants or transplants from mismatched family donors. CR1 was defined based on standard morphological and clinical criteria.
Cytogenetic risk status was based on conventional cytogenetics data not taking into account molecular analysis. Five hundred and eight patients had high-risk cytogenetics and had either monosomies in chromosomes 5 or 7 (n = 163), 11q23 anomalies (n = 96) or a complex karyotype (n = 249). A total of 2297 patients were classified as intermediate risk based on normal karyotype (n = 1527) or on various other cytogenetic anomalies (n = 770). A total of 169 patients had good risk cytogenetics, either inv16, t (8;21) or t (15;17) .
The EBMT is a voluntary organization comprising more than 500 transplant centers mainly from Europe. Accreditation as a member centre requires submission of minimal essential data (MED-A form) from all consecutive patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of transplantation. Informed consent for transplantation and data collection was obtained locally according to the regulations applicable at the time of transplantation. Since January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT following the 1975 Helsinki Declaration.
Statistical analysis was descriptive and employed log-rank comparisons for the univariate assessment of the impact of baseline characteristics on survival end points. End points studied were overall survival (OS) and leukemia-free survival (LFS). Secondary end points were incidence of disease relapse or progression (RI), of NRM and of acute grade II-IV and chronic GvHD. The probabilities for OS and LFS were estimated from the time of HSCT using the Kaplan-Meier product-limit estimate 22 and were compared by the log-rank test in univariate analysis. Estimates of NRM and RI were calculated using cumulative incidence rates to accommodate competing risks, and were compared using Gray's test. 23, 24 Multivariate analyses of OS were performed using Cox regression modeling. Proportional hazards assumptions were checked using the Grambsch-Therneau residual-based test. 25 All P-values o0.05 were considered significant. Variables included in multivariate models were either significant at the 0.2 level in univariate analysis or unbalanced between the groups, or known to have an impact on outcome studied. All tests were two sided. The type-1 error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 19 (SPSS Inc./IBM, Armonk, NY) and R 3.0.1 (R Development Core Team, Vienna, Austria) software packages.
RESULTS
The median follow-up of surviving patients was 46 and 41 months, in both the groups. The two groups, that is, MAC and RIC differed by many variables. MAC recipients were significantly younger (47.6 vs 53.8 years), had a shorter interval from diagnosis to transplantation (143 vs 165 days), were more frequently male (53 vs 48%), had less frequently poor-risk cytogenetics (19 vs 22%) , received less frequently stem cells from an unrelated donor (20 vs 33%) and had more frequently marrow as a stem cell source (36 vs 7%; Table 1 ) and as a consequence lower EBMT risk scores. Abbreviations: HSCT = hematopoietic stem cell transplantation; LFS = leukemia-free survival; MAC = myeloablative intensity conditioning; NRM = nonrelapse mortality; OS = overall survival; RI = relapse incidence; RIC = reduced intensity conditioning. Abbreviations: CI = confidence interval; leukemia-free survival; MAC = myeloablative intensity conditioning; NRM = nonrelapse mortality; OS = overall survival; RI = relapse incidence; RIC = reduced intensity conditioning.
Unrelated donors were either HLA matched or had mismatches in 23.5% both in the RIC and in the MAC groups. As outcomes did not differ among unrelated donor recipient pairs with or without HLA mismatches, these groups are not presented separately. The reasons for receiving RIC conditioning were age (n = 323), comorbidities (n = 199), protocol (n = 504), whereas in 599 patients it was not recorded. Table 2 shows similar OS and LFS in both groups, but a lower RI and a higher NRM incidence in the MAC compared with the RIC group. Acute grade II-IV GvHD was higher with MAC, whereas the incidence of chronic GvHD did not differ significantly.
In univariate analysis by cytogenetic risk group (Table 3) the OS was higher with RIC in low-risk AML (55 ± 5% vs 77 ± 7% MAC vs RIC P o 0.01) but not in intermediate (61 ± 1% vs 62 ± 2%, NS) or poor-risk patients (42 ± 3% vs 40 ± 3%, NS; Figures 1a and b for OS and LFS). The RI was lower with MAC in poor (36 ± 3% vs 51 ± 3%, P o0.0001) and intermediate risk (21 ± 1% vs 30 ± 1%, P o 0.0001), but not in low-risk AML (19 ± 4% vs 13 ± 5%, P = 0.31). NRM was higher in MAC vs RIC in all three cytogenetic risk groups. Figure 2 shows RI and NRM incidence in patients with high-risk AML according to the conditioning regimen. Our original hypothesis that MAC conditioning is superior to RIC for high-risk AML was not supported by the current findings: the RI was lower with MAC vs RIC in both intermediate and poor cytogenetic risk categories (Figure 2 right), but this gain was offset by higher NRM incidence with more intensive conditioning (Figure 2 
DISCUSSION
This large observational study tested the hypothesis that patients with cytogenetically defined low-risk AML might benefit from decreased conditioning intensity, whereas high-risk AML patients may have better results with MAC regimens, based on potentially lower RI with more intense treatment. This hypothesis was tested in an intermediate age group of 40-60 years, where both MAC or RIC are commonly used, without precise formal recommendation how to choose one over the other. The populations were of approximately equal size with 45% of the 2974 patients included receiving a variety of RIC regimens, whereas 55% received MAC regimens. The two groups were not well balanced for other risk factors known to be associated with outcome: RIC patients were older, had a longer interval from diagnosis to transplant, had more commonly unrelated donors, used more commonly peripheral blood instead of marrow as a stem cell source and a higher number received ATG as part of the conditioning. These differences were carefully adjusted for in multivariate analysis, although even with insufficient correction for differences between groups, they would have more likely favored MAC over RIC conditioning. The reasons for receiving RIC conditioning were only known in about two-thirds of the patients and was either given as based on age and comorbidities or more commonly protocol driven. The reason why these patients received an allogeneic HSCT in CR1 is not known; careful evaluation of their cytogenetic data did not show any additional anomalies with the exception of 39 patients in whom various additional cytogenetic anomalies were described. The results showed RIC regimens to be associated with less NRM but a higher RI. NRM was higher in all cytogenetic risk groups (the difference did not reach significance in the low-risk AML group, but we ascribe this to the smaller cohort of low-risk AML patients, as the absolute differences are similar). Conversely, MAC regimens were associated with lower RI in patients with intermediate-and high-risk AML. The net effect was that LFS and OS were similar in patients receiving RIC and MAC in the intermediate-and high-risk AML groups, with a small but significant advantage for RIC in the low-risk group. This difference should not be overestimated as, in general, patients with low-risk AML are not recommended to undergo allogeneic HSCT in CR1 by most groups of investigators and, indeed, in the current data set, low-risk AML comprised only 7 and 4% of the patients in the MAC and RIC groups, respectively.
Comparisons between RIC and MAC regimens have been done systematically by many groups of investigators, most commonly showing lower NRM risks but higher RI with less intensive conditioning. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Our study is unique in identifying patients of an intermediate age with known cytogenetic risk classification to address the question of a possible interaction between cytogenetic risk groups and possible advantages or disadvantages of higher conditioning intensity.
This survey has several limitations that should be overcome in future prospective studies. The groups differed by many covariates. The decision algorithms used by the treating physicians for choosing one regimen or the other were not known. We lack data on comorbidities, crucial for careful comparisons. In addition, leukemia risk stratification was based on cytogenetic information only, and did not use the more modern molecular information such as FLT3 mutations. 26 The issue of why low-risk patients received HSCT is not resolved. Obviously, an observational registry cannot answer these questions. We also lack data on minimal residual disease, a finding that could have constituted a reason to opt for HSCT in a given patient. RIC patients had a longer interval from diagnosis to transplantation and possibly had more pretransplant consolidation treatment although precise data on pretransplant therapy is lacking. A recently published study showed advantages for allogeneic HSCT in CR1 in a group of patient that by today's standards is considered to be low-risk. 27 This shows that the recommendation to transplant intermediate-high-risk patients in CR1 and low-risk patients only after relapse may not be universally accepted. The definition of the middle-aged categories as being aged 40-60 years is somewhat arbitrary. The choice came out of discussions within the HOVON/SAKK study group where a plan for a prospective study was prepared that was later dismissed. The cutoffs proved to be well suited for the present analysis as the patients were split by 1638 in the MAC and 1336 in the RIC group. RIC and MAC groups are not homogenous as these combine different conditioning regimens. We analyzed carefully for heterogeneity in outcomes in the MAC and the RIC groups. We found only minor differences, none for OS, LFS and NRM, which were only significant for relapse incidence in the RIC group, the fludarabine+busulphan group being associated with a lower relapse incidence. These data are therefore not shown here and outcomes are provided for the pooled RIC and MAC groups. Finally, changes in conditioning regimens are undertaken, where intensity is adapted by changing some drugs or schedules to convey less toxicity.
In summary, in patients aged 40-60 years, MAC conditioning has no advantage over RIC, in spite of RIC transplant recipients being generally in a poorer risk category. We confirm lower relapse rates but higher TRM risks with MAC as compared with RIC. We fail to show superiority of MAC in patients with high-risk cytogenetics, but there appears to be an advantage for RIC over MAC in the small cohort of patients with low-risk leukemia. Figure 2. NRM and RI in patients with genetically defined high-risk AML by conditioning intensity. Lower relapse incidence is offset by higher NRM.
